Lexicon Pharmaceuticals Inc (LXRX)

17.30
NASDAQ : Health Care
Prev Close 17.30
Day Low/High 0.00 / 0.00
52 Wk Low/High 13.01 / 19.62
Avg Volume 861.30K
Exchange NASDAQ
Shares Outstanding 105.24M
Market Cap 1.86B
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Lexicon Pharmaceuticals Reports Positive Top-Line Results In Phase 3 InTandem3 Study For Sotagliflozin In Patients With Type 1 Diabetes

Sotagliflozin Demonstrates Statistically Significant Benefit in Primary Endpoint

First Week of January 2018 Options Trading For Lexicon Pharmaceuticals (LXRX)

Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading this week, for the January 2018 expiration.

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

Karyopharm Therapeutics falls 18%; Lexicon rises on drug approval.

Lexicon To Report Fourth Quarter And Year End 2016 Financial Results On March 3, 2017

Conference Call and Webcast to Follow

4 Smaller Biotech Names Worth Researching

4 Smaller Biotech Names Worth Researching

Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.

7 Things to Watch in Biotech Now

7 Things to Watch in Biotech Now

M&A, drug approvals and Trump are all on my watch list.

These 3 Biotech Stocks Are Already Moving Wildly on Thursday

These 3 Biotech Stocks Are Already Moving Wildly on Thursday

Here are some names that have caught our eye.

Lexicon Begins Phase 1 Clinical Trial Of Locally-acting SGLT1 Inhibitor, LX2761, For Potential Treatment Of Diabetes

Lexicon Begins Phase 1 Clinical Trial Of Locally-acting SGLT1 Inhibitor, LX2761, For Potential Treatment Of Diabetes

New Oral, Small Molecule Investigational Drug Is Designed to Inhibit SGLT1 in the GI Tract with Minimal Systemic Absorption

First Week of LXRX February 2017 Options Trading

First Week of LXRX February 2017 Options Trading

Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading this week, for the February 2017 expiration.

Lexicon Reports Positive Top-line Results In Second Pivotal Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes

Lexicon Reports Positive Top-line Results In Second Pivotal Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes

Conference call and webcast December 21, 2016 at 8:30 a.m. Eastern Time

Notable Friday Option Activity: LXRX, WTW, XBIT

Notable Friday Option Activity: LXRX, WTW, XBIT

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Lexicon Pharmaceuticals, Inc. , where a total volume of 6,103 contracts has been traded thus far today, a contract volume which is representative of approximately 610,300 underlying shares (given that every 1 contract represents 100 underlying shares).

Lexicon Reports Top-Line Results From Phase 2 Clinical Trial Conducted In Collaboration With JDRF

Lexicon Reports Top-Line Results From Phase 2 Clinical Trial Conducted In Collaboration With JDRF

Study Conducted in Young Adults with Type 1 Diabetes and High Baseline A1C

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AYR, CRCM, TG Downgrades: ADPT, AMZN, ANGI, ARNC, BKD, BWXT, CAJ, CALX, CSGP, EMR, HZO, LXRX, MNK, MYGN, NTRA, PBI, TCO, TRI Initiations: PFGC Read on to get TheStreet Quant Ratings' detailed report: